Dedicated to enabling surgical administration of novel cell and gene therapies.
The world’s first clinical use of the left atrial appendage (LAA) for epicardial micrograft transplantation during left ventricular assist device (LVAD) implantation was carried out with EpiHeart devices.
The article published in Frontiers in Cardiovascular Medicine marks the start of pioneering clinical studies, where the mechanisms of action of micrograft transplantation are studied with LVAD patients. We want to congratulate Prof. Dr. Jan Schmitto and his interdisciplinary Heart-Team at MHH, Germany, for the great work done for this first patient. Access the case article from the link below.
EpiHeart is a University spin-off company leveraging over 10 years of dedicated research conducted on three continents. We are based in Helsinki, Finland, where we continue collaboration with University of Helsinki, Helsinki University Hospital "HUS" and Aalto University.
EpiHeart is dedicated to enable new treatments that improve long term survival and quality of life of cardiac patients. Our initial focus is in Cardiac Micrograft Therapy™. The pre-clinical and clinical results indicate positive effects on ventricular wall structure and scar size - critical factors contributing to heart failure.
EpiHeart is conducting clinical studies. We are open for collaboration with EU and US based cardiac surgery units and distributors. Our collaboration covers also research and commercial partnerships related to advanced cell and gene therapies that could be administered surgically.
Company profile video (English, Finnish and German subtitles available)